- 第1日 5月15日（水） P会場（多目的ホール）
Monoclonal antibodies (mAbs) are being used increasingly for treating several diseases such as cancer, autoimmune diseases and other chronic diseases. Most of the therapeutic mAbs are produced in yeast or mammalian cell lines that yield mixtures of Fc glycoforms, which are similar to human glycoforms but not completely identical. Glycoengineering is a promising technique to control the glycosylation profiles so as to improve safety, clinical efficacy, and effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Quality evaluation of the glycoengineered mAbs e.g., monitoring specific transformation and change in relative quantities of a set of glycans between glycoengineered mAb vs the mAb produced in CHO cell lines can be achieved using LC-MS with tandem MS based methods. SimGlycan software allows creation of LC-MS templates for target glycans, facilitating rapid and accurate identification of the glycans. Results are exported into MS excel files enabling comparative evaluation of glycoengineered mAbs using MS methods.